If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Hormonal treatment isolated versus hormonal treatment associated with electrotherapy for pelvic pain control in deep endometriosis: Randomized clinical trial
School of Medical Sciences, Department of Obstetrics and Gynecology, University of Campinas, Alexander Fleming, 101, Cidade Universitária, Campinas, SP, 13083-881, Brazil
School of Medical Sciences, Department of Obstetrics and Gynecology, University of Campinas, Alexander Fleming, 101, Cidade Universitária, Campinas, SP, 13083-881, Brazil
Medical School, Department of Obstetrics and Gynecology, University of São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 255 - Cerqueira César, São Paulo, SP, 05403-000, Brazil
Medical School, Department of Obstetrics and Gynecology, University of São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 255 - Cerqueira César, São Paulo, SP, 05403-000, Brazil
School of Medical Sciences, Department of Obstetrics and Gynecology, University of Campinas, Alexander Fleming, 101, Cidade Universitária, Campinas, SP, 13083-881, Brazil
The aim of the study was to evaluate the clinical effectiveness of complementary treatment using self-applied electrotherapy treatment for pain control over the standard hormonal treatment alone for deep infiltrative endometriosis (DIE).
Study design
Multicentre randomized clinical trial. We included a hundred-one participants with DIE in electrotherapy (n = 53) (hormonal treatment + electrotherapy) or control group (n = 48) (only hormonal treatment) by 8 weeks of follow-up. The primary measurement was chronic pelvic pain (CPP) using a visual analogue scale (VAS) and deep dyspareunia. The secondary outcomes were the quality of life by endometriosis health profile (EHP-30) and sexual function by female sexual function index (FSFI).
Results
CPP relief was observed only in the electrotherapy group (pre:7.11 ± 2.40, post:4.55 ± 3.08, p < 0.001). In terms of deep dyspareunia, improvements were observed for both groups (electrotherapy pre:2.02 ± 0.54–1.36 ± 0.96, p < 0.001; control pre:1.95 ± 0.86–1.68 ± 0.82, p = 0.006). Considering the secondary outcomes, a higher total score post-treatment for the EHP-30 was noted in both groups. Regarding sexual function, there was a statistically significant improvement in the FSFI score for the electrotherapy group (p < 0.001), with an increase in the scores for lubrication and pain domains (p = 0.013 and p < 0.001).
Conclusions
Electrotherapy treatment using transcutaneous electrical nerve stimulation proved to be a good complementary option for pain control, showing benefits in the reduction of CPP and deep dyspareunia and improving patient’s quality of life and sexual function.
].At least 20 % of patients still present residual symptoms. In these cases, complementary treatments may be considered. A recent systematic review revealed strategies such as acupuncture and the practice of exercises to control the symptoms, however only acupuncture was effective [
Studies using electrotherapeutic resources as complementary treatment for CPP not related to endometriosis showed an analgesic effect with low side effects, and benefits to some pelvic pain complaints related to women's health. [
] A randomized clinical trial has shown the efficacy in relieving pelvic pain symptoms using two different electrotherapeutic devices (acupuncture and self-applied electrotherapy) in women with DIE [
Effectiveness of complementary pain treatment for women with deep endometriosis through Transcutaneous Electrical Nerve Stimulation (TENS): randomized controlled trial.
The aim of the present study was to evaluate the clinical effectiveness of complementary treatment using self-applied electrotherapy treatment for pain control over the standard hormonal treatment alone for endometriosis, describing its influence on the quality of life (QoL) and sexual function (SF) of women with DIE.
Materials and methods
A multicenter randomized controlled trial study was approved by the research ethics committee from the Universities. The protocol was registered in the ClinicalTrials.gov (number NCT02769052) on May 10th, 2016. The participants were recruited from the Endometriosis Outpatients Clinic of centers from June 2016 to March 2018 and all of them signed an informed consent term. This study followed the CONSORT guidelines for randomized clinical trial.
Inclusion criteria: women at menacme, presenting DIE diagnosed by specialized transvaginal ultrasound or by magnetic resonance. All of them were using continuous hormonal treatment for at least 3 months and reported pelvic pain symptoms (CPP and/or deep dyspareunia). Exclusion criteria: pregnancy, pacemaker, decreased skin sensitivity, allergy to gel or electrode, epilepsy, cardiac arrhythmia, osteosynthesis in the application region, cancer, acute inflammatory pelvic disease, cognitive deficiency and difficulty to understand instructions and/or to use the instruments.
Participants were randomly placed into two groups: electrotherapy group (hormonal treatment plus self-applied electrotherapy) and control group (only hormonal treatment). These women were instructed not to stop drug treatment for endometriosis during the study. The randomization was carried out by groups of 20 cases by means of a lottery using sealed opaque envelopes. Each envelope contained the electrotherapy group (n = 10) or the control group (n = 10). Each time twenty patients were included; the lottery was restarted until the sample size was completed. The same researcher included and applied this randomized method in the two centers.
We describe in Table 1 the interventions applied in this study and primary and secondary outcomes measures. A secondary analysis was performed according to the same protocol when the control group, after the 8-weeks follow-up, used self-applied TENS.
Table 1Detailed description of interventions applied and the primary and secondary outcomes measures.
INTERVENTIONS
Electrotherapy group (self-applied TENS + hormonal treatment)
Control group (hormonal treatment only)
The participants were treated with a self-applied transcutaneous electrical nerve stimulation device (TENS) (commercially available as Tanyx®). This device was registered in the National Agency of Sanitary Surveillance (ANVISA). - Device parameters: frequency: 85 Hz; pulse duration: 75 μs; intensity options: 10, 20, or 30 mA (instructions: the participant was instructed to choose a perception of the electrical stimulus that was “strong, but comfortable”, always at the sensitive threshold). - Technical specifications: the device has an on/off button; a 3-volt lithium battery, lasting for 6 h of continuous application, with 46.5 mm diameter circular gel patch and 1.8 mm thickness; 7.0 ± 0.5 pH. This gel patch (contact with the skin), consisting of water, glycerol, allylamine, and potassium chloride, is applied to the contact metal bases only once and remains fixed until the battery is finished. The device is approximately 15 cm in size and has 10 cm distance between the centers of the electrodes. - Application method: the device was used in the parasacral region (S3-S4 position) twice a day, 20 min per application, for 8 weeks (Fig. 1). Each woman received written instructions and the physical therapist demonstrated its use step-by-step during the evaluation. The device was positioned and turned on so that the participant could have the sensation of the electrical stimulus and could answer her questions. - Follow-up: once a month consultation was scheduled for each patient to monitor the device usage. - Symptoms notes: they were instructed to take notes of their symptoms throughout the 8 weeks.
The participants were followed-up while they were using a hormonal treatment for endometriosis. - Follow-up: the participants were also instructed to maintain hormonal treatment for endometriosis and no intervention was performed. - Symptoms notes: they would take notes about their symptoms throughout the 8 weeks. - Additional method: after the end of the follow-up period, women in this group were also invited to participate in the electrotherapy treatment for 8 weeks according to the same protocol used for the initial proposal (secondary analysis).
PRIMARY MEASURES
- Pelvic pain symptoms: were evaluated before and after 8 weeks of treatment. CPP, dyschezia, dysuria, dysmenorrhea were evaluated by the Visual Analog Scale (VAS, 0–10 points); deep dyspareunia, using deep dyspareunia scale (DDS) (0–3 points: zero, no pain during intercourse until three for intense pain, which requires the interruption of intercourse). [
Effectiveness of complementary pain treatment for women with deep endometriosis through Transcutaneous Electrical Nerve Stimulation (TENS): randomized controlled trial.
] We made a comparison between pelvic pain scores, pre and post 8 weeks of follow-up, by VAS and deep dyspareunia scale, and using a home pain diary.
SECONDARY MEASURES
- Quality of life and sexual function: we also accessed the Endometriosis health profile (EHP-30) and Female Sexual Function Index (FSFI) pre and post 8 weeks of treatment. EHP-30 consists of 53 questions: 30 in a core questionnaire and the 23 other questions, set up in a modular questionnaire, evaluating six domains, including work, children, intercourse, medical, treatment, and infertility. The lower the total score, the better the QoL. FSFI consists of 19 questions divided into six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. A lower value for the total score is associated with a worse SF. - Symptoms notes: the participants also took daily notes using a “pain diary”. In these notes, all pelvic symptoms could be recorded daily (CPP, dyschezia, dysuria, pain during spotting - VAS), and pain during sexual intercourse (DDS). They also noted down any other medication ingested for pain. For the secondary analysis of the control group, the same scales were used.
Categorical variables and their comparison between groups were described by relative and absolute frequencies, by the chi-square and exact Fisher tests. Numeric variables were described in terms of mean, median, and standard deviation, performed by the Mann-Whitney test. Data analysis was intention-to-treat. Wilcoxon test was performed for comparison pre and post-treatment between the groups (initial protocol) and for secondary analysis for the control group. A p-value ≤ 0.05 was considered statistically significant. Statistical analysis was performed by the SAS System for Windows (Statistical Analysis System, version 9.2) and R for Windows (version 3.5.1).
For sample size calculation, to evaluate pelvic pain, 30 women (15 in each group) were required, considering the randomized controlled trial. [
Effectiveness of complementary pain treatment for women with deep endometriosis through Transcutaneous Electrical Nerve Stimulation (TENS): randomized controlled trial.
] However, to address the secondary outcomes of SF and detect differences related to the SF for the total score of FSFI, we considered a difference between the mean equal to 5 points (alpha 0.05 and power of the test 0.80) according to previous studies [
]. However, the values for standard deviation (SD) in these studies have proven to be variable. We propose a new way of estimating it by estimating its weighted value [
]. This estimate was made by considering the maximum (max) FSFI value (36) minus the limit value between sexual dysfunction score (SDS) and normality (26.5) multiplied by this limit minus the minimum (min) value of the scale (2) divided by the maximum value minus the minimum value of the scale, resulting in an average of approximately 6.85 points as described by the formula below. Considering a two-sided test, we estimated a sample size of 30 individuals per group. The final sample size was 36 individuals per group, considering a drop-out rate of 20 %.
Results
A flow chart for randomized controlled trials is presented in Fig. 2. One hundred and thirty-eight women were assessed as eligible, but a hundred and one randomly participated in the follow-up. These women were allocated into: electrotherapy group (n = 53) and control group (n = 48).
Fig. 1Self-applied transcutaneous electrical nerve stimulation (TENS) (Tanyx® - Register in the ANVISA nº80542090001) positioned in the sacral region of the participant (Photo authorized by the participant).
Sociodemographic and clinical characteristics of the 101 participants are in Table 2. Mean age electrotherapy (n = 53) and control groups (n = 48) were 35.06 ± 6.17 and 37.21 ± 6.51 years old, respectively. The intercourse median frequency was once per week for both groups. From the onset time of symptoms to the diagnosis, it took from 3 to 5 years, on average. A history of at least one endometriosis surgery per women was reposted in both groups. Women were using medication for endometriosis for 29.53 ± 29.10 and 24.04 ± 20.87 months for the electrotherapy and control groups, respectively, being the most frequent progestin (84 % and 81 % for each group, respectively). The sociodemographic aspects related to age at onset of symptoms and diagnosis of endometriosis was statistically different (p = 0.015 and 0.027, respectively).
Table 2Main sociodemographic and clinical characteristics of women with deep endometriosis in the electrotherapy group (n = 53) and control group (n = 48).
Characteristics
Electrotherapy group (n = 53)
Control group (n = 48)
Mean ± SD
Median/min-max
Mean ± SD
Median/ min-max
p-value
Age (years)
35.06 ± 6.17
35.0
37.21 ± 6.51
37.0
0.082
Ethnicity White Non-white
64.15(34) 35.85(19)
60.42(29) 39.58(19)
0.192
Marital status (%) With partner Without partner
79.25(42) 20.75(11)
83.33(40) 16.57(8)
0.600
Body mass index (Kg/m²)
26.49 ± 5.13
25.7
26.09 ± 3.72
25.9
1.000
Parity (number of children)
0.81 ± 1.05
0.0
0.98 ± 1.17
1.0
0.573
Parity (%) 0 1 ≥2
49.06(26) 26.42(14) 24.53(13)
52.08(25) 16.67(8) 31.25(15)
0.460
Number of intercourse (frequency per week)
1.57 ± 1.26
1.0
1.21 ± 1.20
1.0
0.073
Age at onset of symptoms (years)
21.48 ± 8.55
20.0
26.35 ± 10.28
26.5
0.015
Age at diagnosis of endometriosis (years)
28.36 ± 6.72
27.0
31.32 ± 6.84
31.0
0.027
Type of diagnosis (%) Transvaginal ultrasound Magnetic resonance imaging Surgery Biopsy
43.40(23) 15.09(8) 39.62(21) 1.89(1)
56.25(27) 22.92(11) 20.83(10) 0.0
0.102
Number of surgeries for Endometriosis
1.40 ± 1.90
1.0
0.88 ± 0.94
1.0
0.243
Time from the last surgery (months) a
56.8 ± 47.9
7−168
59.8 ± 49.2
7−156
0.779
Type of surgical procedurea Laparotomy Videolaparoscopy No answer
13.2 (9) 23.5 (16) 5.8 (4)
16.1 (11) 29.4 (20) 7.3 (5)
0.999
Time of use of the medication for endometriosis (months)
29.53 ± 29.10
18.0
24.04 ± 20.87
15.5
0.616
Type of medication (%) Progestin Combined oral contraceptive (COC)
84.91(45) 15.09(8)
81.25(39) 18.75(9)
0.891
Work position (%) b Seated Standing Seated and standing
51.28(20) 41.03(16) 7.69(3)
38.24(13) 55.88(19) 5.88(2)
0.411
Physical activity (%) No Yes
64.15(34) 35.85(19)
75.00(36) 25.00(12)
0.238
Fisher’s test or test for categorical variables comparison. Mann-Whitney for numerical variables comparison.
a Only those participants who have at least one surgery were considered in the analysis – Electrotherapy (n = 36) and control group (n = 29).
b Only those participants who were employed were considered in the analysis - Electrotherapy group (n = 39) and Control group (n = 34).
Pelvic pain evaluation, pre and post-treatment are described in Table 3. Chronic pelvic pain improved in the electrotherapy group (VAS decreased from 7.11 ± 2.40–4.55 ± 3.08, p < 0.001, 36 % decrease) but this was not observed in the control group (VAS from 7.33 ± 2.09–7.06 ± 2.33, p = 0.554, 3.68 % decrease). A reduction in the deep dyspareunia scale for the electrotherapy group (from 2.02 ± 0.54–1.36 ± 0.96, p < 0.001, a 32.67 % decrease) was observed and for control group, the difference was from 1.95 ± 0.86–1.68 ± 0.82, p = 0.006, 13.84 % decrease. The other pelvic pain complaints were related to as being mild or moderate, with values above 6 points in the VAS.
Table 3Comparison of treatment effects in the electrotherapy group (association with hormonal treatment) and control group (hormonal treatment only) on complaints of pelvic pain, quality of life (EHP-30) and sexual function (FSFI) in women with deep endometriosis.
Electrotherapy group (n = 53)
Control group (n = 48)
Pretreatment
Post-treatment
Pretreatment
Post-treatment
Pelvic Pain
Mean ± SD
Median
Mean ± SD
Median
Difference
p value a
Mean ± SD
Median
Mean ± SD
Median
Difference
p value a
p value of difference b
Chronic Pelvic Pain (VAS)
7.11 ± 2.40
8.0
4.55 ± 3.08
5.0
−2.55 ± 2.98
<0.001
7.33 ± 2.09
7.5
7.06 ± 2.33
7.5
−0.27 ± 2.18
0.554
<0.001
Deep dyspareunia (DDS)
2.02 ± 0.54
2.0
1.36 ± 0.96
2.0
−0.67 ± 0.98
<0.001
1.95 ± 0.86
2.0
1.68 ± 0.82
2.0
−0.27 ± 0.55
0.006
0.091
Dyschezia (VAS)
4.83 ± 4.09
5.5
3.04 ± 3.67
1.0
−1.79 ± 3.28
<0.001
3.75 ± 3.98
1.5
2.83 ± 3.55
0.0
−0.92 ± 2.65
0.022
0.761
Frequency of evacuation (per week)
5.17 ± 5.80
3.0
5.85 ± 6.05
4.0
0.67 ± 2.38
0.030
4.42 ± 3.46
3.0
4.35 ± 2.38
4.0
−0.06 ± 3.42
0.441
0.603
Dysuria (VAS)
1.79 ± 2.95
0.0
1.23 ± 2.41
0.0
−0.56 ± 2.13
0.034
1.25 ± 2.77
0.0
1.40 ± 2.84
0.0
0.15 ± 1.32
0.750
0.992
Pain during spotting (VAS)
2.29 ± 3.92
0.0
2.19 ± 3.67
0.0
−0.10 ± 2.35
0.867
2.31 ± 3.98
0.0
2.90 ± 4.05
0.0
0.58 ± 4.11
0.368
0.340
QUALITY OF LIFE Endometriosis Health Profile (EHP-30)
Core questionnaire
Pain domain
50.81 ± 27.11
54.55
37.95 ± 28.89
36.36
−12.86 ± 19.49
<0.001
47.96 ± 23.49
48.86
42.99 ± 23.23
43.18
−4.97 ± 18.86
0.048
0.290
Control and powerless domain
63.76 ± 26.12
66.67
41.27 ± 32.26
45.86
−22.48 ± 25.83
<0.001
59.11 ± 26.94
a
52.17 ± 28.05
54.17
−6.94 ± 18.22
0.009
0.087
Emotion domain
59.12 ± 23.94
62.50
44.10 ± 27.53
41.67
−15.02 ± 22.02
<0.001
54.34 ± 24.78
54.17
50.87 ± 27.56
54.17
−3.47 ± 18.60
0.205
0.199
Social support domain
58.02 ± 24.92
62.50
43.87 ± 30.70
37.50
−14.15 ± 27.60
<0.001
45.83 ± 25.96
46.88
39.32 ± 26.29
43.75
−6.51 ± 22.48
0.061
0.587
Self-image domain
50.16 ± 29.35
50.00
39.78 ± 30.99
33.33
−10.38 ± 25.26
0.001
42.01 ± 30.70
41.67
42.53 ± 31.43
50.00
0.52 ± 15.98
0.982
0.740
Core questionnaire score
56.37 ± 20.59
53.45
41.40 ± 25.87
41.67
−14.98 ± 19.65
<0.001
49.85 ± 21.95
48.77
45.58 ± 23.35
43.45
−4.28 ± 12.70
0.043
0.305
Modular questionnaire
Work domain
23.96 ± 29.29
10.00
17.83 ± 23.13
0.00
−6.13 ± 21.07
0.049
20.52 ± 26.02
10.00
16.04 ± 23.25
0.00
−4.48 ± 16.38
0.057
0.834
Children domain
15.33 ± 31.07
0.00
13.44 ± 29.09
0.00
−1.89 ± 11.86
0.500
11.98 ± 23.20
0.00
9.38 ± 18.68
0.00
−2.60 ± 14.80
0.281
0.865
Intercourse domain
61.13 ± 33.61
70.00
40.85 ± 35.02
30.00
−20.28 ± 31.74
<0.001
48.75 ± 33.33
60.00
44.17 ± 31.26
45.00
−4.58 ± 23.13
0.139
0.667
Medical domain
17.22 ± 26.99
0.00
13.68 ± 21.27
0.00
−3.54 ± 25.55
0.429
15.23 ± 25.65
0.00
8.85 ± 19.12
0.00
−6.38 ± 31.36
0.087
0.103
Treatment domain
40.88 ± 28.88
41.67
28.30 ± 26.57
25.00
−12.58 ± 21.60
<0.001
28.65 ± 27.23
29.17
32.12 ± 29.32
29.17
3.47 ± 21.32
0.243
0.580
Infertility domain
30.90 ± 38.50
0.00
28.89 ± 36.01
0.00
−2.00 ± 22.56
0.560
20.44 ± 32.71
0.00
14.45 ± 27.90
0.00
−5.99 ± 24.49
0.144
0.047
Modular questionnaire score
31.57 ± 16.82
32.64
23.83 ± 17.40
22.71
−7.74 ± 13.35
<0.001
24.26 ± 14.51
22.85
20.83 ± 13.61
16.84
−3.43 ± 8.45
0.006
0.479
Total questionnaire score
43.97 ± 17.03
42.15
32.61 ± 20.38
32.66
−11.36 ± 15.48
<0.001
37.06 ± 16.03
36.03
33.21 ± 16.66
28.71
−3.85 ± 8.53
0.005
0.593
SEXUAL FUNCTION Female Sexual Function Index (FSFI)
Desire
3.31 ± 1.30
3.00
3.40 ± 1.32
3.60
0.09 ± 0.68
0.403
2.91 ± 1.12
3.00
2.73 ± 1.09
2.40
−0.18 ± 1.03
0.372
0.026
Arousal
3.44 ± 1.32
3.60
3.74 ± 1.08
3.90
0.30 ± 1.34
0.156
3.21 ± 0.83
3.30
3.15 ± 1.12
3.30
−0.06 ± 1.16
0.560
0.018
Lubrication
3.81 ± 1.30
3.60
4.11 ± 1.25
4.20
0.29 ± 0.91
0.013
3.97 ± 1.25
3.90
4.16 ± 1.20
4.20
0.19 ± 1.09
0.278
0.867
Orgasm
4.12 ± 1.34
4.40
4.39 ± 1.12
4.40
0.28 ± 1.15
0.356
3.62 ± 1.44
4.00
3.70 ± 1.35
3.60
0.07 ± 1.15
0.592
0.019
Satisfaction
4.14 ± 1.35
4.40
4.44 ± 1.30
4.80
0.29 ± 1.15
0.390
4.25 ± 1.40
4.80
3.85 ± 1.43
4.00
−0.40 ± 0.91
0.014
0.042
Pain
2.60 ± 0.98
2.80
3.50 ± 1.50
3.60
0.90 ± 1.47
<0.001
2.96 ± 1.34
2.80
3.05 ± 1.29
3.20
0.10 ± 0.92
0.478
0.212
Total score
21.42 ± 5.04
21.30
23.58 ± 4.78
23.50
2.15 ± 4.52
0.001
20.93 ± 5.20
22.20
20.64 ± 5.54
20.70
−0.28 ± 3.65
0.953
0.011
a Wilcoxon test for comparison variables (pre and post-treatment). b Mann-Whitney test for comparison of the difference values between the groups. Intention to treat (ITT) analysis.
Legend: VAS (Visual Analog Scale): 0–10 points (zero: without pain to ten: intense pain) / DDS (Deep Dyspareunia Scale): 0–3 points (zero: without pain to three: intense pain).
Data from the pain diary showed a reduction in the number of days with pain, with difference between the first and eighth week in the electrotherapy (from 3.27 to 2.22, p = 0.028, 32.11 % decrease), but there was no difference for control group (from 4.55 to 4.07, p = 0.203, 10.54 % decrease). Considering the VAS applied to chronic pelvic pain, the reduction was observed from the 3rd week until the end of treatment in the electrotherapy group (Fig. 3). There was an expressive reduction in the average of CPP in the first week of treatment compared to the average in the evaluation (from 7.11 to 3.27) for the electrotherapy group. Over the 8 weeks of follow-up, the electrotherapy group took seven days of medication, in comparison to eighteen days in the control group (p = 0.005).
Fig. 3Description of the distribution of VAS values based on annotations of daily pain control for electrotherapy and control groups throughout 8 weeks of treatment.
Quality of life (EHP-30) showed an improvement in all domains of the core questionnaire for electrotherapy group (reduction in the core score from 56.37 ± 20.59–41.40 ± 25.87, p < 0.001, 26.55 % decrease). In control group, statistical significances were observed for pain and, control and powerless domains, which also impacted the core questionnaire score (reduction from 49.85 ± 21.95–45.58 ± 23.35, p = 0.043, 8.56 % decrease). In modular questionnaire score, both groups showed a reduction (p < 0.001 for electrotherapy, p = 0.005 for control group). The total questionnaire score showed improvement for both groups, with no statistical significance for the pre and post intervention (p = 0.593) (Table 3).
There was an improvement in pain complaints during intercourse (score reduction from 2.02 ± 0.54–1.36 ± 0.96, p < 0.001 in the DDS) in electrotherapy group. A reduction was also observed in the EHP-30 intercourse domain score (from 61.13 ± 33.61–40.85 ± 35.02, <0.001). An improvement was observed in the deep dyspareunia scale in the control group (from 1.95 ± 0.86–1.68 ± 0.82, p = 0.006), but the EHP-30 intercourse domain showed no statistical reduction (48.75 ± 33.33–44.17 ± 31.26, p = 0.139) (Table 3, Table 4).
Table 4Comparison of treatment effects in the control group in two moments: hormonal treatment only (period of follow-up) and hormonal treatment associated to electrotherapy treatment (period of treatment) on complaints of pelvic pain, the quality of life (EHP-30) and sexual function (FSFI) in women with deep endometriosis.
CONTROL GROUP (n = 36)
Hormonal treatment only (period of follow-up – 8 weeks)
Hormonal treatment + TENS (period of treatment – 8 weeks)
Pre (t1)
Post (t2)
Post (t3)
Mean ± SD
Mean ± SD
Mean ± SD
p-value
PELVIC PAIN COMPLAINTS
Chronic Pelvic Pain (VAS)
7.57 ± 1.43
7.14 ± 2.07
4.93 ± 2.73
<0.001 bc
Deep dyspareunia (DDS)
2.20 ± 0.83
1.80 ± 0.77
1.40 ± 1.10
0.004 ab
Dyschezia (VAS)
3.80 ± 3.97
2.50 ± 3.44
1.83 ± 2.72
0.038 ab
Frequency of evacuation (per week)
4.90 ± 2.40
4.37 ± 2.34
5.87 ± 4.79
0.001 bc
Dysuria (VAS)
1.60 ± 3.15
1.83 ± 3.22
1.43 ± 2.80
0.639
Pain during spotting (VAS)
2.17 ± 3.83
2.67 ± 3.96
1.73 ± 3.30
0.145
QUALITY OF LIFE Endometriosis Health Profile (EHP-30)
Core questionnaire
Pain domain
49.05 ± 24.07
42.36 ± 23.35
25.81 ± 31.40
<0.001 bc
Control and powerless domain
60.65 ± 28.07
53.12 ± 28.41
25.81 ± 31.40
<0.001 abc
Emotion domain
55.90 ± 25.11
53.24 ± 27.42
31.02 ± 29.42
<0.001 bc
Social support domain
48.44 ± 26.49
43.75 ± 26.35
29.51 ± 31.22
0.011 bc
Self-image domain
44.44 ± 31.31
45.14 ± 32.02
28.01 ± 30.93
0.005 bc
Core questionnaire score
51.70 ± 22.88
47.52 ± 23.84
27.23 ± 26.85
<0.001 bc
Modular questionnaire
Work domain
21.25 ± 27.08
15.83 ± 24.36
10.69 ± 19.79
0.003 c
Children domain
13.89 ± 25.14
10.42 ± 19.71
7.29 ± 18.99
0.142
Intercourse domain
48.19 ± 33.21
45.97 ± 31.16
28.61 ± 31.70
0.007 bc
Medical domain
17.01 ± 27.78
10.24 ± 20.76
8.16 ± 20.58
0.049 c
Treatment domain
34.72 ± 27.71
37.96 ± 30.04
20.83 ± 26.39
0.005 bc
Infertility domain
20.49 ± 32.55
14.06 ± 26.02
8.16 ± 24.81
0.081
Modular questionnaire score
25.93 ± 14.07
22.42 ± 12.89
13.96 ± 16.18
<0.001 abc
Total questionnaire score
38.81 ± 15.89
34.97 ± 16.16
20.59 ± 20.39
<0.001 abc
SEXUAL FUNCTION Female Sexual Function Index (FSFI)
Desire
2.72 ± 1.08
2.56 ± 1.00
3.06 ± 1.47
0.362
Arousal
2.91 ± 0.68
3.09 ± 1.13
3.36 ± 1.21
0.798
Lubrication
3.68 ± 1.12
4.25 ± 1.15
4.31 ± 1.26
0.038 ab
Orgasm
4.56 ± 1.48
3.73 ± 1.37
3.77 ± 1.32
0.720
Satisfaction
4.08 ± 1.30
3.64 ± 1.44
4.32 ± 1.40
0.195
Pain
2.95 ± 1.25
3.09 ± 1.29
3.64 ± 1.41
0.085
Total score
19.89 ± 4.05
20.36 ± 4.91
22.46 ± 6.36
0.150
Friedman test for comparison of variables in three times. t1 = Evaluation (pre treatment); t2 = reevaluation of period of the hormonal treatment only (8 weeks) and beginning of the hormonal + TENS treatment period; t3 = reevaluation of the period of hormonal treatment + TENS (8 weeks). Wilcoxon test for comparison variables (pre and post-treatment) between two times → a t1 x t2; b t2 x t3; c t1 x t3 (p < 0.05).
In the SF assessed by FSFI, the electrotherapy group demonstrated improvement in the lubrication domain (3.81 ± 1.30–4.11 ± 1.25, p = 0.013), pain during intercourse (2.60 ±a 0.98–3.50 ± 1.50, p < 0.001), and in total score (from 21.42 ± 5.04–23.58 ± 4.78, p = 0.001, 9.16 % increase), suggesting a general improvement in SF. In control group, the only statistical difference observed was in satisfaction domain (4.25 ± 1.40–3.85 ± 1.43, p = 0.014), demonstrating a decrease in satisfaction, besides FSFI score has not improved (from 20.93 ± 5.20–20.64 ± 5.54, p = 0.953). There was an improvement in the total score for the electrotherapy group for the pre and post intervention values (p = 0.011) (Table 3).
Secondarily, the aspects related to complaints of pain, QoL and SF of women in the control group who accepted to participate in the electrotherapy treatment for 8 weeks were analyzed. We observed that CPP improved after the use of electrotherapy in this group (p < 0.001). Similarly, all domains of the quality of life questionnaire showed improvement after analgesic resource, as well as in the lubrication domain of FSFI (Table 4).
Based on pain diary, some side effects observed were: six participants in complete amenorrhea reported spotting (16.2 %) in electrotherapy group and it was associated with mild pain (VAS: 3.33 ± 2.25) during the days of spotting. In the control group, this complaint was not reported. Therefore, no long-term side effects are expected and no participant contacted us reporting any complaints related to the use of the device.
Discussion
This clinical trial evaluated electrotherapy as a complementary treatment for DIE in comparison with a control group. Patients in both groups had a diagnosis of deep endometriosis and they were using hormonal treatment. The eight-week follow-up showed that the use of self-applied transcutaneous electrical nerve stimulation (TENS) has benefits in the relief of CPP. This treatment also induced an improvement in the QoL and in SF.
Endometriosis can be considered a chronic disease, demanding pharmacological treatment for the relief of pain complaints, normally hormonal treatment. However, sometimes the pharmacological treatments are insufficient for pain control. [
] Our results showed that electrotherapy can be considered a complementary intervention option to relieve pelvic pain symptoms allied to medical treatment, improving the QoL.
Previous studies using electrotherapy demonstrated the benefits to relieve CPP not related to endometriosis. [
]. We observe an improvement of CPP pre and post-treatment and from the 3rd week of the pain diary. This benefit is due to an electrical stimulus using the sensorial pathways to send impulses to the spinal cord in the ascending pathways, blocking the harmful visceral stimulus from endometriotic pelvic inflammatory lesions using high-frequency application (85 Hz). The high frequency is described in literature as any frequency above 70−100 Hz. Such a stimulus is thought to work in the Control Gate Theory [
]. This effect can be seen in our study, in which the daily use of electrotherapy demonstrated pelvic pain relief.
Deep dyspareunia is a symptom associated to DIE. Rectovaginal endometriosis and lesions in uterosacral ligaments promote pain due to traction of inelastic tissue, making the uterus less mobile. [
]. Hormonal treatment with progestin has also been shown to be appropriate. Hormonal therapy reduces pain during intercourse in two-thirds of women with rectovaginal lesions [
]. In this context, for those who do not respond, another treatment is required. Our study demonstrated improvement for dyspareunia using electrotherapy associated to hormonal treatment or using hormonal treatment exclusively. But the intervention using TENS decreased the intake of analgesic drugs, and electrotherapeutic treatment has fewer side effects than analgesic drugs [
]. Considering this context, pain management is an important decision. Our results showed that pelvic pain relief in the electrotherapy group positively affected all domains of the EHP, demonstrating improvement in the control of pain, control and powerless, emotion, social support, self-image, work and treatment domains. This can also be observed when the control group, in a second moment, received the intervention.
Dyspareunia and depressive symptoms are associated with impaired sexual functioning in women with endometriosis, whereas sexual functioning in their male partners is not affected.
] Our study verified an improvement in the lubrication and pain (dyspareunia) domains and total score of the FSFI in electrotherapy group. The improvement was also observed in the intercourse domain in quality of life questionnaire. Possibly the disruption of the pain cycle (pain-fear-tension) contributed to sexual intercourse improvement. [
Dyspareunia and depressive symptoms are associated with impaired sexual functioning in women with endometriosis, whereas sexual functioning in their male partners is not affected.
]. The same observations could be seen when we analyze the control group that was subsequently submitted to electrotherapeutic intervention.
The benefits could be seen better and in detail in the pain diary. Comparing the weeks, there was a statistically significant improvement from the 3rd week until the end of treatment with the electrotherapy device. We believe the use of a pain diary can contribute towards a better understanding of symptom evolution in the course of the treatment for both the health professional and patient. In this context, the patient better comprehends the importance of treatment, as it favors the patient's visualization of the pain variation and thus the patient observes progress that contributes positively to her condition. This leads to more realistic pain perception and its progression during a follow-up or treatment period, since the pain reported can be skewed by a more recent intense pain memory.
Although we described the intention-to-treat analysis, the results from the per protocol analysis was performed and point in the same direction.
Despite the benefits showed, the main limitations are the short follow-up treatment time, considering the disease chronicity and the long-term electrotherapy treatment use is still unknown in this population. Strengths include the assessment of an electrotherapy protocol associated with hormonal treatment using a self-applied device, compared to a control group using hormonal treatment only. Besides that, it also includes the use of a pain diary, with a more rigid and reliable control for the use and effectiveness of our intervention. The results contributed to identifying the effectiveness of complementary treatment.
Conclusions
Electrotherapy treatment using transcutaneous electrical nerve stimulation proved to be a good option for endometriosis pain control, showing benefits in the reduction of chronic pelvic pain and deep dyspareunia and improving QoL and SF. Thus, this therapeutic tool can be considered a complementary treatment for DIE.
Declaration of Competing Interest
The authors report no declarations of interest.
Acknowledgements
This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brazil (CAPES) - Finance Code 001. The authors would like to thank Murilo Guimarães Borges and Helymar da Costa Machado for the contribution with the statistical analysis and review of the collected data and manuscript. We would like to thank the donations of the devices for this research, received in June 2015 from Medcell by Moacyr Ramos Bighetti (Registration with ANVISA nº 08.054209.001 - Lot: 04201501BR - Manufacture: 042015). The current manuscript was part of the PhD thesis “Self-applied transcutaneous electrical nerve stimulation (tens) in the complementary treatment for pain and the impact on the quality of life and sexual function on women with deep endometriosis: a systematic review with meta-analysis and a multicenter study” by Ticiana Aparecida Alves de Mira under the tutorial of Cristina Laguna Benetti Pinto and presented of the Postgraduate Program of Obstetrics and Gynecology from the School of Medical Sciences of the University of Campinas on 27th February 2019.
References
Burney R.O.
Giudice L.C.
Pathogenesis and pathophysiology of endometriosis.
Effectiveness of complementary pain treatment for women with deep endometriosis through Transcutaneous Electrical Nerve Stimulation (TENS): randomized controlled trial.
Dyspareunia and depressive symptoms are associated with impaired sexual functioning in women with endometriosis, whereas sexual functioning in their male partners is not affected.
30648-5&id=gr1.jpg){kind=link}
30648-5&id=gr2.jpg){kind=link}
30648-5&id=gr3.jpg){kind=link}